ZYBERNO
Stock Report
Updated Aug 26, 2026

Tevogen Inc. (TVGNW)

Healthcare • NASDAQ

$0.05

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
10.0/100
POOR BUSINESS
Tevogen Inc. (TVGNW) scores 10/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-440.3%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Tevogen Inc. (TVGNW) stock report — Zyberno Score 10/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, TVGNW generated -$1.51M in Owner Earnings. Capital was deployed as follows: $133.00K invested in capital expenditures. Reinvestment rate: 0.8%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.05
Market Cap:$176.92K

Valuation Multiples (1)

Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$486.59K

Price Action & Momentum (1)

% of 52-Week High:59.0%
B. Profitability Assessment

Return Metrics (4)

ROA:-466.7%
Reinvestment Rate:0.8%
Fundamental Growth Rate (g):-3.5%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$24.05K
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Growth (Linear) (1)

Net Income Growth Rate (Linear):100.0%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:0.33x
Quick Ratio:0.33x
Cash Ratio:0.18x

Leverage Analysis (1)

Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:-4,141,324.00
Cash And Cash Equivalents:1,082,155.00
Long Term Debt:$1.06M
Net Debt:$309.68K
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$21.40M

Bottom Line Performance (3)

Net income TTM: -$21.61M
Linear Growth: 100.0%
📊 Click to view full TVGNW Net Income analysis & methodology →
Income Before Tax:$0.00
Ebitda Ttm:-21,222,640.00

Operating Expenses (5)

Operating Expenses:21,402,928.00
R And D Expense:11,633,894.00
Sga Expense:9,769,034.00
Income Tax Expense:$4.75K
Interest Expense:-351,709.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$4.73M
Current Assets:$2.01M
Ppe Net:109,772.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:13,616,501.00
Current Liabilities:6,150,584.00
Long Term Debt:$1.06M
Short Term Debt:$327.74K

Equity & Capital (3)

Equity:-$8.89M
Retained Earnings:-$150.87M
Common Stock:800,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:2,829,264.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:2,849,592.00
C. Cash Flow Analysis

Operating Activities (2)

-$11.75M-$11.89M

Investment Activities (2)

Investing Cash Flow:$0.00
Capital Expenditures Ttm:133,000.00

Financing Activities (3)

Financing Cash Flow:$2.87M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:873,702.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:180,288.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-11.11
-$11.11
Earnings Per Share Ttm:-$5.64

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$3.22

Book Value & Capital (2)

Book Value Per Share:-$2.32
Cash Per Share:0.28

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:20.00
Quality Score:10.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$1.51M

Damodaran Growth Analysis (2)

Reinvestment Rate:0.8%
Fundamental Growth Rate (g):-3.5%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Net Income Growth Rate (Linear):100.0%
C. Company Profile & Context

Corporate Information (6)

Symbol:TVGNW
Company Name:Tevogen Inc.
Sector:Healthcare
Industry:Biological Products, (No Diagnostic Substances)
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:3.83M
Shares Outstanding Basic:3.83M
Shares Outstanding Diluted:3.83M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-26 16:51:38 UTC
Data Timestamp:2026-08-26T16:51:38.441874
Scroll to Top